Kalaris Therapeutics Inc. (NASDAQ:KLRS – Get Free Report)’s stock price traded up 15.4% during mid-day trading on Monday . Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a report on Wednesday, May 13th. Finally, TD Cowen assumed coverage on shares of Kalaris Therapeutics in a research report on Monday, June 15th. Insider Transactions at Kalaris TherapeuticsIn other news, Director Srinivas Akkaraju bought 244,300 shares of Kalaris Therapeutics stock in a transaction on Wednesday, May 20th. Recommended StoriesReceive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.